<DOC>
	<DOCNO>NCT00617760</DOCNO>
	<brief_summary>The purpose study healthy toddler previously immunize MenC infection complete primary immunization series PCV-7 ( 3 vaccination ) infancy demonstrate concomitant administration single dose MenC-TT vaccine PCV7 booster influence immune response seven pneumococcal strain contain PCV7 compare administration PCV7 alone , influence immune response MenC-TT vaccine compare administration MenC-TT vaccine alone .</brief_summary>
	<brief_title>Safety Immunogenicity Study MenC-TT Vaccine ( NeisVac-C ) Toddlers Previously Immunized With PCV7 ( Prevenar® )</brief_title>
	<detailed_description />
	<mesh_term>Meningitis</mesh_term>
	<mesh_term>Pneumococcal Infections</mesh_term>
	<mesh_term>Meningitis , Bacterial</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Male female subject eligible participation study : toddler , age 12 18 month clinically healthy ( i.e . physician would reservations vaccinate MenC conjugate vaccine , and/or PCV7 outside scope clinical trial ) parents/legal guardian ( ) understand nature study , agree provision , provide write informed consent parents/legal guardian ( ) agree keep Subject Diary receive complete primary series pneumococcal conjugate vaccine ( 3 vaccination PCV7 first year life accord official vaccination calendar recommendation ) Subjects excluded participation study : history vaccinerelated contraindicate event , e.g . serious reaction first application PCV7 vaccine high fever &gt; = 40ºC associated vaccination , generalize allergic reaction within 48 hour first application vaccine know sensitivity allergy component vaccines previously vaccinate MenC vaccine already receive PCV 7 booster ( 4th vaccination ) rash dermatological condition injection site could interfere injection site reaction evaluation suffer disease ( e.g . autoimmune disease ) undergo form treatment ( e.g . systemic corticosteroid ) expect influence immunological function history meningococcal serogroup C and/or invasive pneumococcal infection receive blood product immunoglobulins within 90 day study entry administration product plan study period currently history serious disease ( e.g . cardiac , renal , autoimmune , neurologic ) administer investigational drug within 6 week prior study entry concurrently participate clinical study include administration investigational product parent /legal guardian ( ) dependent relationship study investigator study team member . Dependent relationship include close relative ( i.e. , child grandchild , partner/spouse , sibling ) well employee investigator site conducting study .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>18 Months</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>